Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Dividends Paid - Preferred Dividends Paid - Preferred Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Lifecore Biomedical, Inc. \De\ (LFCR) Cash from Restructuring (2020 - 2023)

Lifecore Biomedical, Inc. \De\ has reported Cash from Restructuring over the past 4 years, most recently at -$3.5 million for Q2 2023.

For Q2 2023, Cash from Restructuring rose 39.13% year-over-year to -$3.5 million; the TTM value through May 2023 reached $640000.0, changed N/A, while the annual FY2024 figure was $1.4 million, 119.06% up from the prior year.
Cash from Restructuring for Q2 2023 was -$3.5 million at Lifecore Biomedical, Inc. \De\, down from $2.6 million in the prior quarter.
Over five years, Cash from Restructuring peaked at $6.7 million in Q3 2020 and troughed at -$5.8 million in Q2 2022.
A 4-year average of $1.3 million and a median of $1.1 million in 2020 define the central range for Cash from Restructuring.
On a YoY basis, Cash from Restructuring climbed as much as 1238.04% in 2022 and fell as far as 206.12% in 2022.
Year by year, Cash from Restructuring stood at $1.1 million in 2020, then tumbled by 42.95% to $627000.0 in 2021, then fell by 10.21% to $563000.0 in 2022, then plummeted by 728.06% to -$3.5 million in 2023.
Business Quant data shows Cash from Restructuring for LFCR at -$3.5 million in Q2 2023, $2.6 million in Q1 2023, and $563000.0 in Q4 2022.